- Home
- CODA vs ENTX Comparison
CODA vs ENTX Comparison
Compare CODA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CODA | ENTX |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 50.9M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CODA | ENTX |
|---|---|---|
| Price | $11.84 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 366.0K | 168.7K |
| Earning Date | 03-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | 0.08 | ★ 0.25 |
| Revenue | ★ $20,316,161.00 | $42,000.00 |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $141.25 | ★ $4.44 |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.76 | $0.91 |
| 52 Week High | $18.00 | $3.22 |
Technical Indicators
Market Signals| Indicator | CODA | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 45.23 |
| Support Level | $7.47 | $1.00 |
| Resistance Level | $12.22 | $1.61 |
| Average True Range (ATR) | 0.76 | 0.15 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 25.91 | 40.35 |
Price Performance
Historical ComparisonAbout CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.